
US Stock Focus Electronic Arts rebounded from key major support
Share this:

Medium-term technical outlook (1-3months) on Electronic Arts (EA)
Key technical elements
- The recent 19% plunge seen in EA has managed to stall at a key major support of 99.60 which is the gapped up seen on 10 May 2017 and the lower boundary of the ascending channel in place since 08 Feb 2016.
- The rebound from 99.60 key major support indicates that the on-going primary (multi-month) uptrend remains intact coupled with other positive technical elements.
- The daily RSI oscillator has continued to inch higher from a broken descending resistance in place since May 2017 and still has room for further potential upside before it reaches an extreme overbought level of 94%.
- Volume has started to increase and yesterday’ volume is higher versus the average of the previous 3 days. Observations from the daily RSI and volume have indicated that medium-term upside momentum of price action has resurfaced.
- The key medium-term support rests at 109.47 which is defined by the former swing high areas of 27 Nov/18 Dec 2017 and 61.8% Fibonacci retracement of the current up move from 28 Dec 2017 low to yesterday, 18 Jan 2018 high.
Key levels (1 to 3 months)
Pivot (key support): 109.47
Resistances: 122.79 & 132.65
Next support: 99.60
Conclusion
Therefore, Electronic Arts (EA) is likely to have resume its medium-term bullish impulsive upleg. As long as the 109.47 key medium-term pivotal support holds, EA may see a further push up to retest its current all-time high at 122.79 before targeting the next significant resistance at 132.65 (upper boundary of the ascending channel from 08 Feb 2016 & 1.00 Fibonacci projection of the up move from 08 Feb 2016 low to 30 Sep 2016 high projected from 05 Dec 2017.
On the other hand, failure to hold above 109.47 should negate the preferred bullish tone to see a slide back to retest the 99.60 major support.
Chart is from eSignal
Related tags:
Latest market news
View more newsOpen an account today
Experience award-winning platforms with fast and secure execution.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.

SK Hynix IPO: Everything You Need to Know About SK Hynix
Learn everything you need to know about the SK Hynix IPO, including its Nasdaq listing, valuation, financials, ownership, competitors and investment risks.

Nasdaq 100 Outlook: Broadcom Extends Slide, Palantir Reversal Signal
Nasdaq 100 slides as AI funding fears bite, with Broadcom extending losses and Palantir flashing a potential reversal at resistance.

ASX 200 Market Wrap: Big Four Bounce, FMG Surges, CSL Lags
ASX 200 posts its best day in three months as big four banks rebound, FMG breaks higher and CSL continues to lag the market.
From time to time, StoneX Financial Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.






